

GLAXOSMITHKLINE PLC

Form 6-K

April 11, 2011

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending April 2011

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons Discharging Managerial Responsibility or Connected Persons in the Ordinary shares of GlaxoSmithKline plc in respect of the under-mentioned persons arising from the purchase of Ordinary shares at a price of £12.23 per Ordinary share on 8 April 2011 through the Company's ShareReward Plan ("the Plan"):

Mr A P Witty Acquisition of 41 Ordinary shares under the Dividend Reinvestment element of the Plan

Mr S Bicknell Acquisition of 41 Ordinary shares under the Dividend Reinvestment element of the Plan

Mr E J Gray Acquisition of 41 Ordinary shares under the Dividend Reinvestment element of the Plan

Mr S Hussain Acquisition of 8 Ordinary shares under the Dividend Reinvestment element of the Plan

Dr D Pulman Acquisition of 13 Ordinary shares under the Dividend Reinvestment element of the Plan

Mr D Redfern Acquisition of 41 Ordinary shares under the Dividend Reinvestment element of the Plan

Ms C Thomas Acquisition of 41 Ordinary shares under the Dividend Reinvestment element of the Plan

Dr P J Vallance

Mrs V A Whyte Acquisition of 17 Ordinary shares under the Dividend Reinvestment element of the Plan

Acquisition of 32 Ordinary shares under the Dividend Reinvestment element of the Plan

The Company and the above-mentioned persons were advised of this information on 11 April 2011.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte
Company Secretary
11 April 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: April 11 2011

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc